Mycophenolate Mofetil Dispersible Tablets: Prevention of Organ Rejection in Transplant Patients
ProcurenetShort description
Mycophenolate Mofetil Dispersible Tablets: Prevention of Organ Rejection
- Mycophenolate Mofetil Dispersible Tablets ensure effective prevention of organ rejection in kidney, heart, or liver transplant recipients.
- Pharmaceutical-grade immunosuppressive agent, Mycophenolate Mofetil, is the key active ingredient in these tablets.
- The tablets are readily dissolved in water for easy administration and are absorbed effectively by the body, providing controlled release of the agent for optimal therapeutic efficacy.
- Carefully co-formulated with other prescribed medications like cyclosporine and adrenocortical hormone to enhance comprehensive immunosuppressive therapy and ensure improved patient outcomes.
- Common side effects include headache, diarrhea, nausea, vomiting, abdominal pain, and insomnia among others.
-
Procurenet Team Tshim Sha Tsui
Hong Kong
3 years
Description
Mycophenolate Mofetil Dispersible Tablets: A Proactive Solution for Organ Rejection
Mycophenolate Mofetil Dispersible Tablets is an FDA-approved drug, designed for the prevention of organ rejection in patients who have undergone kidney, heart, or liver transplantation. This medication is a key player in the long journey to successful transplantation, acting as an immunosuppressant by reducing the activity of the body's immune system to prevent it from attacking the new organ.
Indications and Usage
Designed for use primarily in conjunction with cyclosporine and adrenocortical hormones, these tablets are a valuable, notable solution for holistic post-transplant care.
Product Characteristics
- Molecular Formula: C23H31NO7
- Molecular Weight: 433.5 g/mol
- CAS Number: 128794-94-5
- Density: 1.25 g/cm³
- LogP: 2.6
- Solubility: Soluble in acetone, hardly soluble in alcohol and in acetonitrile
Precautionary Measures
This medication is not optimal for everyone. Ringing with the importance of individual health care, it is advised that patients undergo a consultation with their doctor prior to beginning a cycle of Mycophenolate Mofetil Dispersible Tablets.
Prominent Features
- The product is of pharmaceutical grade, ensuring a high quality and effective solution for prevention of organ rejection.
- Available for sale across a widespread number of markets including North America, Central/South America, Western Europe, Eastern Europe, Australasia, Asia, Middle East, and Africa.
